CVnCoV
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- CVnCoV
- Accession Number
- DB15844
- Description
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- CV07050101
- SARS-CoV-2 mRNA vaccine
- External IDs
- CVnCoV
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Rego GNA, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, Mamani JB, Gamarra LF: Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2. Vaccines (Basel). 2020 Aug 25;8(3). pii: vaccines8030474. doi: 10.3390/vaccines8030474. [PubMed:32854391]
- Speiser DE, Bachmann MF: COVID-19: Mechanisms of Vaccination and Immunity. Vaccines (Basel). 2020 Jul 22;8(3). pii: vaccines8030404. doi: 10.3390/vaccines8030404. [PubMed:32707833]
- CureVac & Covid-19 [Link]
- Smart Patients [Link]
- Regulatory News [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus / Severe Acute Respiratory Syndrome 1 2 Active Not Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus / Severe Acute Respiratory Syndrome 1 2, 3 Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) 1 1 Active Not Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus / Severe Acute Respiratory Syndrome 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on September 17, 2020 12:37 / Updated on September 18, 2020 02:47